Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
The Union Minister noted that heat stress contributes to a rise in both communicable diseases such as dengue and non-communicable conditions like cardiovascular disorder
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
Subscribe To Our Newsletter & Stay Updated